Specialty Pharmacy: Expert Takeaways on Specialty Pharmacy/PBM/Supply Chain/Biosimilar Landscape

Research evidence excerpt

Specialty Pharmacy: Expert Takeaways on Specialty Pharmacy/PBM/Supply Chain/Biosimilar Landscape

IdeaMexpert framed OPCH as still relatively well-positioned, particularly in the near term,

with limited risk of a Stelara-like disruption over the next 2–3 years. They

highlighted that a significant portion of infusion demand remains tied to therapies

such as asthma biologics, IVIG, and other complex infused drugs where biosimilar

pathways are less immediate or more difficult to execute. The expert did note

multiple sclerosis as an area where, while biosimialrs are not expected in the next

~3-5 years, there is a significant amount of profit tied to a few drugs in this space.

Importantly, they remained constructive on the broader infusion market given

continued product flow and structural advantages for scaled players. Overall, it

seems that margin pressure will be manageable within a still-supportive industry

structure.

3. BTSG Viewed Favorably with Disproportionate Exposure to Oncology and

Durable LDD Opportunity: The expert highlighted a constructive setup for BTSG

driven by Onco360’s positioning in oncology, a category where plans remain focused

on cost control but are more hesitant to aggressively shift site of care or override

provider preference. As a result, biosimilar adoption in oncology is more likely to

occur through product substitution than broad channel disruption, preserving the

role of specialty pharmacies such as Onco360. The expert also pointed to a

continued runway for limited distribution drug (LDD) wins, supported by a high-

touch service model and favorable positioning in sensitive populations such as

oncology (other sensitive areas include pediatric and behavioral health), which will

become increasingly important and where BTSG is positioned to win.